Acute facial neuralgia related to initiation of emtricitabine/tenofovir for HIV PrEP: a report of two cases in a PrEP demonstration trial.
Sex Health
; 212024 Jan.
Article
em En
| MEDLINE
| ID: mdl-38281491
ABSTRACT
BACKGROUND:
Emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) fixed-dose combination (FTC/TDF) is generally well-tolerated, although treatment-related adverse events have been reported.METHODS:
We report two cases of persons using FTC/TDF PrEP who had acute neuralgia in a Chinese PrEP demonstration trial.RESULTS:
Neurological symptoms subsided upon treatment discontinuation. Symptoms were reported as similar to one case's previous experiences with dolutegravir (DTG)+FTC+tenofovir alafenamide (TAF) (for PEP), leading to permanent discontinuation of PrEP.CONCLUSION:
Acute facial neuralgia appears to be a rare idiosyncratic adverse event to FTC/TDF.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Infecções por HIV
/
Fármacos Anti-HIV
/
Neuralgia Facial
Limite:
Humans
Idioma:
En
Revista:
Sex Health
Assunto da revista:
DOENCAS SEXUALMENTE TRANSMISSIVEIS
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
China